NRX Pharmaceuticals, Inc.
NRXP • NASDAQ
NRX Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Jonathan C. Javitt, with a market cap of $72.4M.
CEOJonathan C. Javitt
Next Earnings
Upcoming earnings announcement for NRX Pharmaceuticals, Inc.
Date
Thursday, May 14, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.02
Revenue Estimate
$14.3M
Earnings History
Past 12 earnings reports for NRX Pharmaceuticals, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Q4 2025 | $0.20Est: -$0.08 | +350.0% | $983.0KEst: $7.0M | -86.0% |  10-K |
| Nov 17, 2025 | Q3 2025 | -$0.27Est: -$0.05 | -440.0% | $242.0KEst: $10.9M | -97.8% | 10-Q |
| Aug 18, 2025 | Q2 2025 | -$0.98Est: -$0.23 | -326.1% | - | — | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.34Est: -$0.25 | -36.0% | - | — | 10-Q |
| Mar 17, 2025 | Q4 2024 | -$0.77 | — | - | — | 10-K/A |
| Nov 14, 2024 | Q3 2024 | -$0.15Est: -$0.69 | +78.3% | - | — | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$0.75Est: -$0.58 | -29.3% | - | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.74Est: -$0.37 | -100.0% | - | — | 10-Q |
| Mar 28, 2024 | Q4 2023 | -$0.50Est: -$0.70 | +28.6% | - | — | 10-K/A |
| Nov 13, 2023 | Q3 2023 | -$0.70Est: -$1.20 | +41.7% | - | — | — |
| Aug 14, 2023 | Q2 2023 | -$1.20Est: -$1.40 | +14.3% | - | — | — |
| May 16, 2023 | Q1 2023 | -$1.60Est: -$1.40 | -14.3% | - | — | — |